Aperio Group LLC grew its position in shares of LivaNova PLC (NASDAQ:LIVN) by 14.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,290 shares of the company’s stock after buying an additional 1,645 shares during the period. Aperio Group LLC’s holdings in LivaNova were worth $1,648,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System lifted its holdings in LivaNova by 12.7% during the 3rd quarter. Louisiana State Employees Retirement System now owns 13,300 shares of the company’s stock worth $1,649,000 after buying an additional 1,500 shares during the last quarter. Cerebellum GP LLC bought a new position in LivaNova during the 3rd quarter worth approximately $191,000. Fox Run Management L.L.C. lifted its holdings in LivaNova by 23.8% during the 3rd quarter. Fox Run Management L.L.C. now owns 4,873 shares of the company’s stock worth $604,000 after buying an additional 938 shares during the last quarter. Cibc Bank USA bought a new position in LivaNova during the 3rd quarter worth approximately $227,000. Finally, Rhenman & Partners Asset Management AB lifted its holdings in LivaNova by 11.8% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 95,000 shares of the company’s stock worth $11,777,000 after buying an additional 10,000 shares during the last quarter. 87.38% of the stock is currently owned by institutional investors.
A number of research analysts have commented on the company. BidaskClub raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a report on Thursday, November 1st. Jefferies Financial Group increased their target price on LivaNova to $150.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research downgraded LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Finally, Stifel Nicolaus raised their price target on LivaNova from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, September 17th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $126.50.
In related news, insider David S. Wise sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $123.43, for a total value of $185,145.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $121.58, for a total value of $121,580.00. The disclosure for this sale can be found here. In the last three months, insiders sold 9,058 shares of company stock worth $1,078,683. Company insiders own 0.41% of the company’s stock.
Shares of NASDAQ LIVN opened at $118.81 on Friday. The company has a market capitalization of $5.97 billion, a P/E ratio of 35.89, a P/E/G ratio of 3.68 and a beta of 0.94. LivaNova PLC has a 12-month low of $76.14 and a 12-month high of $131.54. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.08). The company had revenue of $272.10 million during the quarter, compared to the consensus estimate of $275.03 million. LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the business posted $0.83 EPS. On average, research analysts forecast that LivaNova PLC will post 3.1 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “LivaNova PLC (LIVN) Shares Bought by Aperio Group LLC” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/11/livanova-plc-livn-shares-bought-by-aperio-group-llc.html.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.